United States — Food and Drug Administration & Merck & Co.

United States — Food and Drug Administration: The United States — Food and Drug Administration granted approval for the expanded use of General Atomics' diagnostic test, enabling its use for more cancer types and supporting treatment decisions with Pembrolizumab.

Merck & Co.: Merck & Co. is the developer of Pembrolizumab, and the expanded FDA approval of the companion diagnostic test will likely increase the patient pool for its anti-PD-1 therapy.

United States — Food and Drug Administration: The United States — Food and Drug Administration has approved Inmazeb, a combination of antibodies, to treat Zaire Ebolavirus infection, which Regeneron Pharmaceuticals has donated for potential use in the current outbreak.

Merck & Co.: Merck & Co.>>>'s Ervebo vaccine, effective against the Zaire strain of Ebola, is being considered for potential use against the Uganda — Bundibugyo strain, though its efficacy is still under assessment.

United States — Food and Drug Administration: The United States — Food and Drug Administration classified the recall as Class II and is overseeing the process, ensuring patient safety and regulatory compliance.

Merck & Co.: Merck & Co. is mentioned as a company that has previously recalled drugs due to nitrosamine contamination, providing context to the current event.